Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mersana Therapeutics Inc (MRSN)
NASDAQ:MRSN
RESEARCH TOOLSreports
Mersana Therapeutics (MRSN) Stock Price & Analysis
413 Followers
MRSN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.80 - $6.28
Previous Close$1.97
Volume1.96M
Average Volume (3M)1.58M
Market Cap
$241.05M
Enterprise Value$198.94M
Total Cash (Recent Filing)$75.19M
Total Debt (Recent Filing)$33.08M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 07, 2024EPS Estimate
-$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding122,361,236
10 Day Avg. Volume1,679,776
30 Day Avg. Volume1,580,122
Standard Deviation0.37
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)7.06
Price to Sales (P/S)28.19
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.19
Enterprise Value/Gross Profit5.40
Enterprise Value/Ebitda-1.51
Forecast
1Y Price Target
$6.67Price Target Upside238.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Mersana Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentManagement confirmed that they had seen clinical responses during escalation and commented that they were pleased with the safety profile of XMT-1660, notably absent of common toxicities associated with ADCs including peripheral neuropathy, ocular toxicity, and profound myelosuppression.
Financial PerformanceMersana recorded a net loss of $19.3M in the quarter, narrower than consensus of $31M.
Pipeline ProgressMRSN continues to dose escalate patients in the Phase I study of XMT-2056 following lifting of the clinical hold earlier this year.
Bears Say
Clinical TrialsFollowing the lifting of the clinical hold, dosing has begun again in the Phase 1 dose escalation study of XMT-2056.
CompetitionCaution remains that XMT-1660 will show differentiation versus its three large pharma competitors.
ConfidenceWhile the delay is fairly minor, it doesn't increase confidence in positive data.
---
Ownership Overview
42.43% Insiders
11.84% Mutual Funds
10.72% Other Institutional Investors
35.01% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRSN FAQ
What was Mersana Therapeutics Inc’s price range in the past 12 months?
Mersana Therapeutics Inc lowest stock price was $0.80 and its highest was $6.28 in the past 12 months.
What is Mersana Therapeutics Inc’s market cap?
Currently, no data Available
When is Mersana Therapeutics Inc’s upcoming earnings report date?
Mersana Therapeutics Inc’s upcoming earnings report date is Aug 07, 2024 which is in 16 days.
How were Mersana Therapeutics Inc’s earnings last quarter?
Mersana Therapeutics Inc released its earnings results on May 09, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.178 by $0.018.
Is Mersana Therapeutics Inc overvalued?
According to Wall Street analysts Mersana Therapeutics Inc’s price is currently Undervalued.
Does Mersana Therapeutics Inc pay dividends?
Mersana Therapeutics Inc does not currently pay dividends.
What is Mersana Therapeutics Inc’s EPS estimate?
Mersana Therapeutics Inc’s EPS estimate is -$0.17.
How many shares outstanding does Mersana Therapeutics Inc have?
Mersana Therapeutics Inc has 122,361,240 shares outstanding.
What happened to Mersana Therapeutics Inc’s price movement after its last earnings report?
Mersana Therapeutics Inc reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.178. Following the earnings report the stock price went down -27.647%.
Which hedge fund is a major shareholder of Mersana Therapeutics Inc?
Among the largest hedge funds holding Mersana Therapeutics Inc’s share is Woodline Partners LP. It holds Mersana Therapeutics Inc’s shares valued at 13M.
---
Mersana Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.67 (238.58% Upside)
$6.67 (238.58% Upside)
Hedge Fund Trend
Increased
By 3.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.60%
12-Months-Change
Fundamentals
Return on Equity
-292.19%
Trailing 12-Months
Asset Growth
-33.03%
Trailing 12-Months
Company Description
Mersana Therapeutics Inc
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
---
MRSN Earnings Call
Q1 2024
0:00 / 0:00
---
MRSN Stock 12 Month Forecast
Average Price Target
$6.67
▲(238.58% Upside)
Technical Analysis
Best Analysts Covering MRSN
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
-4.70%
upgraded a buy rating 5 months ago
Copying David Nierengarten's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -4.70% per trade.
---